Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe
You may also be interested in...
Korea’s Health Ministry Selects 43 Innovative Companies For Tax/Funding Benefits
Tax credits, priority for government projects and expanded funding opportunities will support 42 Korean firms and Korea-heavy Otsuka Pharmaceutical with R&D expansion
Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets
SEOUL - South Korea's Ministry of Health and Welfare has selected 21 Korean pharmaceutical manufacturers and 17 medical equipment firms to support these companies in the development of globally competitive new drugs, marketing efforts and U.S. FDA approvals needed for their advancement into the U.S. market
Infectious Diseases Space Wide Open For Partnering Beyond Hep C, Conference Finds
The recent spotlight on hepatitis C doesn't mean that's the only hot area in infectious diseases for deals.